Bechelli 1985.

Methods	Allocation: randomised, stratified by schizophrenia subgroups. Blindness: double. Duration: 6months (preceeded by 7 day washout).
Participants	Diagnosis: schizophrenia (RDC). History: >2 episodes, stabilized for 3 months, duration ill ‐ mean 12 years (SD 9 years), informed consent. N=41. Age: range 19‐50 years, mean range 30‐33. Sex: all male. Setting: out‐patient clinic.
Interventions	1. Pipothiazine palmitate: dose mean 75mg/IM/month**, range 50‐125 mg/injection. N=20. 2. Haloperidol decanoate: dose mean 100mg/IM/month, range 50‐100 mg/injection. N=21.
Outcomes	Mental state: BPRS. Leaving the study early. Additional medication. Adverse effects: AIMS, Bordeleau Scale. Unable to use ‐ Global impression: CGI (no data). Weight measures: non‐clinical outcomes (data not usable).
Notes	* Spitzer 1997 ** Mean dose of PP reported as 75 mg in the abstract and 65mg in paper.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear